Effects of a multidomain intervention against cognitive decline on dementia risk profiles - Results from the AgeWell.de trial.
dementia
lifestyle
prevention
randomized controlled trial
risk factor
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
05 Jul 2024
05 Jul 2024
Historique:
revised:
10
05
2024
received:
23
01
2024
accepted:
29
05
2024
medline:
5
7
2024
pubmed:
5
7
2024
entrez:
5
7
2024
Statut:
aheadofprint
Résumé
Dementia risk scores constitute promising surrogate outcomes for lifestyle interventions targeting cognitive function. We investigated whether dementia risk, assessed using the LIfestyle for BRAin health (LIBRA) index, was reduced by the AgeWell.de intervention. Secondary analyses of the AgeWell trial, testing a multicomponent intervention (including optimization of nutrition, medication, and physical, social, and cognitive activity) in older adults with increased dementia risk. We analyzed data from n = 461 participants with complete information on risk/protective factors comprised by LIBRA at the 24-month follow-up. Intervention effects on LIBRA and LIBRA components were assessed using generalized linear models. The intervention reduced LIBRA scores, indicating decreased dementia risk at follow-up (b = -0.63, 95% confidence interval [CI]: -1.14, -0.12). Intervention effects were particularly due to improvements in diet (odds ratio [OR]: 1.60, 95% CI: 1.16, 2.22) and hypertension (OR: 1.61, 95% CI: 1.19, 2.18). The AgeWell.de intervention reduced dementia risk. However, several risk factors did not improve, possibly requiring more intensive interventions. The AgeWell.de intervention reduced dementia risk according to LIfestyle for BRAin health (LIBRA) scores. Beneficial effects on LIBRA are mainly due to changes in diet and blood pressure. A pragmatic lifestyle intervention is apt to reduce dementia risk in an at-risk population.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : German Federal Ministry for Education and Research
ID : 01GL1704A
Organisme : German Federal Ministry for Education and Research
ID : 01GL1704B
Organisme : German Federal Ministry for Education and Research
ID : 01GL1704C
Organisme : German Federal Ministry for Education and Research
ID : 01GL1704D
Organisme : German Federal Ministry for Education and Research
ID : 01GL1704E
Organisme : German Federal Ministry for Education and Research
ID : 01GL1704F
Informations de copyright
© 2024 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388:9‐21.
Mintun MA, Lo AC, Duggan EC, et al. Donanemab in early Alzheimer's disease. N Engl J Med. 2021;384:1691‐1704.
Kumari S, Bagri K, Deshmukh R. Chapter 2 ‐ Dementia: a journey from cause to cure. In: Gupta U, Kesharwani P, eds. Nanomedicine‐Based Approaches for the Treatment of Dementia. Academic Press; 2023:37‐56. doi:10.1016/B978‐0‐12‐824331‐2.00011‐X
Gustavsson A, Norton N, Fast T, et al. Global estimates on the number of persons across the Alzheimer's disease continuum. Alzheimers Dement. 2023;19:658‐670. doi:10.1002/alz.12694
Jönsson L, Wimo A, Handels R, et al. The affordability of lecanemab, an amyloid‐targeting therapy for Alzheimer's disease: an EADC‐EC viewpoint. Lancet Reg Health Eur. 2023;29:100657.
World Health Organization. Global action plan on the public health response to dementia 2017‐2025. 92415134. 2017.
Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet North Am Ed. 2020;396:413‐446.
Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at‐risk elderly people (FINGER): a randomised controlled trial. Lancet North Am Ed. 2015;385:2255‐2263.
Kivipelto M, Ngandu T, Laatikainen T, et al. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population‐based study. Lancet Neurol. 2006;5:735‐741.
Anstey KJ, Cherbuin N, Herath PM. Development of a new method for assessing global risk of Alzheimer's disease for use in population health approaches to prevention. Prev Sci. 2013;14:411‐421.
Schiepers OJG, Köhler S, Deckers K, et al. Lifestyle for brain health (LIBRA): a new model for dementia prevention. Int J Geriatr Psychiatry. 2018;33:167‐175.
McMaster M, Kim S, Clare L, et al. Lifestyle risk factors and cognitive outcomes from the multidomain dementia risk reduction randomized controlled trial, body brain life for cognitive decline (BBL‐CD). J Am Geriatr Soc. 2020;68:2629‐2637. doi:10.1111/jgs.16762
Solomon A, Stephen R, Altomare D, et al. Multidomain interventions: state‐of‐the‐art and future directions for protocols to implement precision dementia risk reduction. A user manual for brain health services‐part 4 of 6. Alzheimers Res Ther. 2021;13:171. doi:10.1186/s13195‐021‐00875‐8
Coley N, Hoevenaar‐Blom MP, van Dalen J‐W, et al. Dementia risk scores as surrogate outcomes for lifestyle‐based multidomain prevention trials‐rationale, preliminary evidence and challenges. Alzheimers Dement. 2020;16:1674‐1685. doi:10.1002/alz.12169
Deckers K, Köhler S, Ngandu T, et al. Quantifying dementia prevention potential in the FINGER randomized controlled trial using the LIBRA prevention index. Alzheimers Dement. 2021;17:1205‐1212.
Hafdi M, Hoevenaar‐Blom MP, Richard E. Multi‐domain interventions for the prevention of dementia and cognitive decline. Cochrane Database Syst Rev. 2021;11:CD013572. doi:10.1002/14651858.CD013572.pub2
Hall A, Barbera M, Lehtisalo J, et al. The Australian national university Alzheimer's disease risk index (ANU‐ADRI) score as a predictor for cognitive decline and potential surrogate outcome in the FINGER lifestyle randomized controlled trial. Eur J Neurol. 2024;31(5):e16238. doi:10.1111/ene.16238
Reitan RM. Trail Making Test: Manual for Administration and Scoring. Reitan Neuropsychology Laboratory; 1986.
Morris JC, Heyman A, Mohs RC, et al. The consortium to establish a registry for Alzheimer's disease (CERAD): I. Clinical and neuropsychological assessment of Alzheimer's Diseas. Neurology. 1989;39(9):1159‐1165.
Baron‐Cohen S, Wheelwright S, Hill J, et al. The “reading the mind in the eyes” test revised version: a study with normal adults, and adults with Asperger syndrome or high‐functioning autism. J Child Psychol Psychiatry. 2001;42:241‐251.
Zülke A, Luck T, Pabst A, et al. AgeWell.de—study protocol of a pragmatic multi‐center cluster‐randomized controlled prevention trial against cognitive decline in older primary care patients. BMC Geriatr. 2019;19:203. doi:10.1186/s12877‐019‐1212‐1
Röhr S, Zülke A, Luppa M, et al. Recruitment and baseline characteristics of participants in the AgeWell.de study‐a pragmatic cluster‐randomized controlled lifestyle trial against cognitive decline. Int J Environ Res Public Health. 2021;18(2):408. doi:10.3390/ijerph18020408
Zülke AE, Pabst A, Luppa M, et al. A multidomain intervention against cognitive decline in an at‐risk‐population in Germany: results from the cluster‐randomized AgeWell.de trial. Alzheimers Dement. 2023;20(1):615‐628. doi:10.1002/alz.13486
Deckers K, van Boxtel MPJ, Schiepers OJG, et al. Target risk factors for dementia prevention: a systematic review and Delphi consensus study on the evidence from observational studies. Int J Geriatr Psychiatry. 2015;30:234‐246.
Twisk J, Bosman L, Hoekstra T, Rijnhart J, Welten M, Heymans M. Different ways to estimate treatment effects in randomised controlled trials. Contemp Clin Trials Commun. 2018;10:80‐85. doi:10.1016/j.conctc.2018.03.008
Anstey KJ, Zheng L, Peters R, et al. Dementia risk scores and their role in the implementation of risk reduction guidelines. Front Neurol. 2022;12:765454. doi:10.3389/fneur.2021.765454
Solomon A, Handels R, Wimo A, et al. Effect of a multidomain lifestyle intervention on estimated dementia risk. J Alzheimers Dis. 2021;82:1461‐1466. doi:10.3233/JAD‐210331
Coley N, Ngandu T, Lehtisalo J, et al. Adherence to multidomain interventions for dementia prevention: data from the FINGER and MAPT trials. Alzheimers Dement. 2019;15:729‐741. doi:10.1016/j.jalz.2019.03.005
Quittschalle J, Stein J, Luppa M, et al. Internet use in old age: results of a German population‐representative survey. J Med Internet Res. 2020;22:e15543.
Röhr S, Arai H, Mangialasche F, et al. Impact of the COVID‐19 pandemic on statistical design and analysis plans for multidomain intervention clinical trials: experience from world‐wide FINGERS. Alzheimers Dement. 2021;7:e12143.
Kivipelto M, Solomon A, Ahtiluoto S, et al. The finnish geriatric intervention study to prevent cognitive impairment and disability (FINGER): study design and progress. Alzheimers Dement. 2013;9:657‐665. doi:10.1016/j.jalz.2012.09.012
Cardona MI, Weißenborn M, Zöllinger I, et al. Physical activity determinants in older German adults at increased dementia risk with multimorbidity: baseline results of the AgeWell. de study. Int J Environ Res Public Health. 2022;19:3164.
French DP, Olander EK, Chisholm A, Mc Sharry J. Which behaviour change techniques are most effective at increasing older adults' self‐efficacy and physical activity behaviour? A systematic review. Ann Behav Med. 2014;48:225‐234. doi:10.1007/s12160‐014‐9593‐z
Cardona MI, Luppa M, Zülke A, et al. Mediating factors associated with physical activity in older adults at increased dementia risk. Am J Alzheimers Dis Other Demen. 2024;39. doi:10.1177/15333175241257849
Thyrian JR. Prävention und Gesundheitsförderung bei Demenz: Änderungsmotivation im Rahmen präventiver Interventionen – empirische Ergebnisse. [Prevention and health promotion in dementia: motivation for change within preventive interventions‐Empirical results]. Nervenarzt. 2023;94:375‐383. doi:10.1007/s00115‐023‐01480‐w
Kivipelto M, Mangialasche F, Snyder HM, et al. World‐wide FINGERS network: a global approach to risk reduction and prevention of dementia. Alzheimers Dement. 2020;16:1078‐1094.
Richter A, Schienkiwitz A, Starker A, et al. Gesundheitsfördernde Verhaltensweisen bei Erwachsenen in Deutschland – Ergebnisse der Soitudie GEDA 2019/2020‐EHIS. Robert Koch‐Institut; 2021.